http://www.fda.gov/cder/drug/infopage/protopic/default.htm
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
The FDA has issued a public health advisory to inform healthcare professionals and patients about a potential cancer risk from use of Protopic (tacrolimus) in the treatment of atopic dermatitis (eczema).